Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Aliskiren

Aliskiren

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Aliskiren

43 trials tracked of Aliskiren: 35 in phase 3 or 4.

43Trials tracked
35Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 19 Phase 3 16 Phase 2 5 Other / NA 3
  1. Phase 4 8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension Completed
  2. Phase 4 Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients Completed
  3. Phase 4 Effect of High and Low Sodium Diets on Blood Pressure in Hypertensive Patients Treated With Aliskiren Completed
  4. Phase 4 Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population Completed
  5. Phase 4 A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension Completed
  6. Phase 4 A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus Completed
Show 37 more trials
  1. Phase 4 The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function Completed
  2. Phase 4 Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal Completed
  3. Phase 4 Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension. Completed
  4. Phase 4 Shiga Microalbuminuria Reduction Trial-2 Completed
  5. Phase 4 Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension Completed
  6. Phase 4 Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus Completed
  7. Phase 4 ALiskiren or Losartan Effects on bioMARKers of Myocardial Remodeling Completed
  8. Phase 4 Effect of Aliskiren and Hydrochlorothiazide on Kidney Oxygenation in Patients With Hypertension Completed
  9. Phase 4 Direct Renin Inhibition Effects on Atherosclerotic Biomarkers Completed
  10. Phase 4 Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus Completed
  11. Phase 4 Effects of Aliskiren on Patient With Heart Failure and a Normal Ejection Fraction Completed
  12. Phase 4 Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients Completed
  13. Phase 4 Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension Completed
  14. Phase 3 Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure Completed
  15. Phase 3 Aliskiren and the Calcium Channel Blocker Amlodipine Combination as an Initial Treatment Strategy for Hypertension Completed
  16. Phase 3 Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS Completed
  17. Phase 3 Safety and Efficacy of Aliskiren 300 mg, 150 mg and 75 mg in Patients With Essential Hypertension Compared to Ramipril 5 mg Completed
  18. Phase 3 Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure Completed
  19. Phase 3 An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age Completed
  20. Phase 3 A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension Completed
  21. Phase 3 Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension Completed
  22. Phase 3 Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients Completed
  23. Phase 3 An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure Completed
  24. Phase 3 Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study Completed
  25. Phase 3 Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone Completed
  26. Phase 3 Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension Completed
  27. Phase 3 A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly Completed
  28. Phase 3 Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE) Completed
  29. Phase 3 A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide. Completed
  30. Phase 2 A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure Completed
  31. Phase 2 Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise Completed
  32. Phase 2 Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome Completed
  33. Phase 2 Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure Completed
  34. Phase 2 Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome Completed
  35. N/A The Effect of Renin Inhibition on Nerve Function in Diabetes Completed
  36. N/A Registry for Ambulant Therapy With RAS-Inhibitors in Hypertension-patients in Germany Completed
  37. N/A The Effect of Aliskiren on Endothelial Function in Pre-Diabetes and Diabetes Completed

Showing the 43 most-cited and recently-updated of 43 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.